ArticleFrontiers in immunology2026
Repeated courses of sequential venetoclax and donor lymphocyte infusions in a patient with relapsed high-risk myelodysplasia following allogeneic stem cell transplantation: a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents the only potentially curative therapy in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, a considerable proportion of patients experience post-transplant relapse, a condition associated with relevant morbidity and an overall dismal prognosis. In this context, the administration of donor lymphocyte infusion (DLI) has been historically used to exploit the graft- Case description: We report here the successful treatment of a patient with high-risk MDS and relapse onset following allo-HSCT. The patient was started on salvage treatment with azacitidine (AZA) and low-dose VEN. Surprisingly, bone marrow cellularity was restored, with rapid improvement of the hematological parameters and recovery of full chimerism as well after a single initial course of AZA/VEN. Two additional courses of AZA/VEN supplemented with DLI were delivered, and then the patient was placed on a maintenance treatment with the sequence of VEN single agent tightly followed by DLI. Six courses of combined VEN/DLI were delivered at 3-month intervals. This innovative strategy proved to be effective in terms of disease control, absence of infectious complications, and quality of life. The patient is presently alive and well in continuous complete remission (CR) 24 months since disease recurrence. The details of his recent clinical history are reported here. Conclusion: Recurrent courses of VEN in combination with DLI may be exploited for CR maintenance in patients with MDS/AML managed for disease recurrence after allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.